NTLA LAWSUIT ALERT: The Gross Law Firm Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Portfolio Pulse from
The Gross Law Firm has initiated a class action lawsuit against Intellia Therapeutics (NTLA) alleging that the company misled investors about its Phase 1/2 study for NTLA-3001. The lawsuit claims that NTLA failed to disclose the declining demand for viral-based editing and the inefficiency of the NTLA-3001 program. On January 9, 2025, Intellia announced a company reorganization, halting NTLA-3001 research and reducing workforce by 27%, causing the stock price to drop from $12.02 to $10.20.
March 26, 2025 | 3:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The class action lawsuit alleges misleading statements about NTLA-3001 study, which could negatively impact investor confidence and stock performance.
The lawsuit and company reorganization suggest potential financial and reputational challenges for Intellia Therapeutics, likely causing short-term negative sentiment and stock price pressure.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100